PAYVANDI, FLORA
PAYVANDI, FLORA
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
ISTH’s new strategic plan 2024-2028: A transformative journey toward shaping the future of thrombosis and hemostasis
2024 F. Peyvandi, P. Angchaisuksiri, T. Reiser
Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial
2024 G. Kenet, B. Nolan, B. Zulfikar, B. Antmen, P. Kampmann, T. Matsushita, C. You, K. Vilchevska, C.N. Bagot, A. Sharif, F. Peyvandi, G. Young, C. Negrier, J. Chi, B. Kittner, C. Sussebach, F. Shammas, B. Mei, S. Andersson, K. Kavakli
Pattern of use and clinical outcomes with rIX‐FP in pediatric/adolescent patients with haemophilia B in Italy: Results from IDEAL real‐world study
2024 P. Giordano, B. Pollio, G. Sottilotta, C. Biasoli, F. Daniele, R. De Cristofaro, F. Peyvandi, M.R. Villa, G. Castaman
Insights on the Development of PRACTICE, A Research-Oriented Healthcare Platform
2024 D. Ahmetovic, A. Angileri, S. Arcudi, C. Bettini, G. Civitarese, M. Colussi, A. Giachi, R. Gualtierotti, S. Mascetti, M. Manzoni, F. Peyvandi, A. Solyman, A. Truma
Gender equity in hemophilia: need for healthcare, familial, and societal advocacy
2024 R. Gualtierotti, I. Garagiola, M. Mortarino, S. Spena, O. Romero-Lux, F. Peyvandi
A case of lymphadenopathies with concomitant multiple acquired hemostasis disorders in an adult female patient
2024 A. Truma, A. Artoni, J.A. Giannotta, M. Caronni, F. Peyvandi
Emicizumab in Type 3 von Willebrand Disease: Report of a Case with an Alloantibody and Literature Review
2024 A.C. Giuffrida, S.M. Siboni, L. Baronciani, G. Poli, G. Gandini, F. Peyvandi
IgM autoantibodies to complement factor H in C3 glomerulopathy
2024 M. Cugno, M.C. Mancuso, F. Depetri, F. Peyvandi, G. Ardissino
Predicting inhibitor development using a random peptide phage-display library approach in the SIPPET cohort
2024 S. Hassan, G. Baselli, L. Mollica, R.L. Rossi, H. Chand, A. El-Beshlawy, M. Elalfy, V. Ramanan, P. Eshghi, M. Karimi, R. Palla, F.R. Rosendaal, F. Peyvandi
Rare bleeding disorders: Advances in management
2024 A. Casini, H. Al‐samkari, C. Hayward, F. Peyvandi
Reappraisal of the conventional hemostasis tests as predictors of perioperative bleeding in the era of rebalanced hemostasis in cirrhosis
2024 A. Tripodi, M. Primignani, R. D'Ambrosio, G. Tosetti, V. La Mura, P. Lampertico, F. Peyvandi
Variant p.Tyr1584Cys: a frequent von Willebrand factor variant in search of von Willebrand disease
2024 O. Seidizadeh, L. Baronciani, P. Colpani, G. Cozzi, A. Ciavarella, S.M. Siboni, F. Peyvandi
Safety and efficacy of combined dual antiplatelet therapy and factor VIII prophylaxis in patients with haemophilia A after acute coronary syndrome
2024 P. Agosti, S.M. Siboni, A. Ciavarella, S. Arcudi, F. Boggio, R. Gualtierotti, F. Peyvandi
Comprehensive investigation of platelet function in patients with cirrhosis
2024 A. Lecchi, G. Tosetti, C. Ghali, S. La Marca, M. Clerici, L. Padovan, E.A. Femia, M. Primignani, V. La Mura, P. Lampertico, F. Peyvandi, A. Tripodi
EAHAD haemophilia gene therapy clinical outcome database (EAHAD‐GTD)
2024 W. Miesbach, A. Boban, P. Chowdary, M. Coppens, M. Crato, V. Jimenez‐yuste, R. Klamroth, M. Makris, G. Mulders, F. Peyvandi
Recommendations for a minimum data set for monitoring gene therapy in hemophilia: communication from the ISTH SSC Working Group on Gene Therapy
2024 W. Miesbach, B. Konkle, P. Chowdary, R. Kaczmarek, F. Leebeek, J. Mahlangu, M. Makris, S.W. Pipe, A. Srivastava, J. Voorberg, G.F. Pierce, F. Peyvandi
Flow-chamber device (T-TAS) to diagnose patients suspected of platelet function defects
2024 A. Lecchi, S. La Marca, L. Padovan, M. Boscarino, F. Peyvandi, A. Tripodi
Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial
2024 S.W. Pipe, P. Collins, C. Dhalluin, G. Kenet, C. Schmitt, M. Buri, V. Jiménez-Yuste, F. Peyvandi, G. Young, J. Oldenburg, M.E. Mancuso, K. Kavakli, A. Kiialainen, S. Deb, M. Niggli, T. Chang, M. Lehle, K. Fijnvandraat
Type 2M/2A von Willebrand disease: a shared phenotype between type 2M and 2A
2024 O. Seidizadeh, L. Mollica, S. Zambarbieri, L. Baronciani, A. Cairo, P. Colpani, G. Cozzi, M.T. Pagliari, A. Ciavarella, S.M. Siboni, F. Peyvandi
Transitioning from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: A simulation study for individuals with severe haemophilia A
2024 S. Agarwal, C. Hermans, W. Miesbach, F. Peyvandi, R. Sidonio, D. Osmond, V. Newman, J. Henshaw, S. Pipe